Differing Phospholipase A2 Receptor (PLA2R) Antibody Decline Kinetics After Obinutuzumab in High-Risk Membranous Nephropathy: Report of Two Cases (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0690; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 59-year-old male with high-risk MN (anti-PLA2R ab 354.8 RU/ml; sCr 168µmol/L; sAlb 17g/L; uPCR 18.77g/g) and virally suppressed HIV on Biktarvy, was given OBI after suboptimal response with Rituximab (RTX) 2g. OBI was well tolerated in the HIV-positive patient, with no adverse virologic or immunologic effects, contributing to limited safety data in this population. Overall, these cases support response-guided OBI dosing in high-risk PLA2R MN refractory to conventional therapy and suggest acceptable safety in HIV-positive patients, although prospective studies are needed to establish individualized dosing strategies."
Clinical • Glomerulonephritis • Human Immunodeficiency Virus • Infectious Disease • Renal Disease • CD4
|
|
Shi Yun Tan; Jason Choo Chon Jun; Kok pan Loo; Jiunn Wong; Hui Zhuan Tan
|